MedTrace Logo

Effects of Vitamin D Supplementation on Muscle Protein Synthesis

NCT06746389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-12-24

No results posted yet for this study

Summary

Background: Healthy adults maintain muscle tissue by continuously building up and breaking down muscle proteins throughout the day. Studies have shown that vitamin D (VitD) is essential for maintaining muscle mass by activating cellular pathways involved in building muscle via muscle protein synthesis (MPS). Although, various candidate molecules have been identified in animal models, it is not known whether these pathways are activated in humans. Interestingly, animal studies indicate that 20% of VitD is stored in human muscle cells, which may help maintain VitD sufficiency during winter in Northern latitudes when there is not much sunlight Objectives: We will investigate whether VitD supplementation increases the MPS response to feeding and exercise, VitD storage in muscle cells, and cellular pathways that are involved in healthy sedentary or moderately active adults.

Methods: Participants will consume either a placebo (sucrose) or the intervention (vitamin D3, 3000IU/day) for 12 weeks in a double-blinded randomised study. Before and after the intervention participants will have body composition measured. Blood and muscle samples will be taken before and after a bout of exercise and ingestion of 20 g protein in order to measure MPS.

Conditions

  • Vitamin D Effects on MPS
  • Placebo Effects on MPS

Interventions

DIETARY_SUPPLEMENT

3000 IU per Day Spray

Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    collaborator OTHER

  • Wageningen University

    collaborator OTHER

  • University of Exeter

    lead OTHER

Principal Investigators

  • Raquel Revuelta Iniesta, PhD · University of Exeter

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-08
Primary Completion
2024-06-23
Completion
2024-10-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06746389 on ClinicalTrials.gov